Hestia Insight Inc. (HSTA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hestia Insight Inc. (HSTA) trades at $0.03756 with AI Score 39/100 (Grade D). Hestia Insight Inc. Market cap: $1.05M, Sector: Technology.
Price as of Jul 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for HSTA: HSTA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HSTA against Technology peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HSTA: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Hestia Insight Inc. (HSTA) Technology Profile & Competitive Position
Hestia Insight Inc. is a Las Vegas-based technology firm delivering specialized strategic consulting and capital market advisory services to small and mid-sized businesses across the healthcare, biotech, and fintech sectors. The company also engages in healthcare technology analysis, medical supply sales management, and comprehensive sales and marketing strategy, positioning itself as a diversified solutions provider in niche markets.
What Is the Investment Thesis for HSTA?
Hestia Insight Inc. operates in a specialized niche, offering strategic consulting and technology solutions to the healthcare, biotech, and fintech sectors, which are characterized by ongoing innovation and demand for expert guidance. The company's diversified service portfolio, encompassing capital market advisory, healthcare technology analysis, and medical supply sales management, positions it to capture revenue streams from multiple angles within these high-growth industries. With a market capitalization of $1.05M, the company represents a micro-cap entity with potential for significant percentage growth from a low base, assuming successful execution of its service offerings and client acquisition. The increasing demand for data analytics and specialized technology solutions across industries, as highlighted by AI insights, provides a favorable market backdrop for Hestia Insight Inc.'s technology-focused services. However, its trading on the OTC Other tier and unknown disclosure status introduce higher inherent risks, including potential volatility and limited public information, necessitating thorough due diligence by investors.
Based on FMP financials and quantitative analysis
HSTA Key Highlights
- Hestia Insight Inc. operates with a market capitalization of $1.05M, reflecting its status as a micro-cap entity within the technology sector.
- The company exhibits a Beta of 0.25, suggesting lower volatility relative to the broader market, though this can be influenced by its OTC listing.
- Hestia Insight Inc. does not currently pay a dividend, consistent with many growth-oriented or smaller technology firms.
- The company's share price of $0.038 and market capitalization of $1.05M (as per AI insight) indicate its micro-cap valuation and potential for significant price sensitivity.
- Hestia Insight Inc. maintains a lean operational structure with 3 employees, focusing on specialized consulting and technology services.
Who Are HSTA's Competitors?
HSTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RSASF RESAAS Services Inc. | $0.26 | -5.37% | $21.5M | 69 |
| WFCF Where Food Comes From, Inc. | $12.60 | +3.19% | $63.5M | 72 |
| RSSS Research Solutions, Inc. | $2.20 | +0.00% | $73.6M | 75 |
| IDN Intellicheck, Inc. | $3.85 | +3.22% | $78.0M | 73 |
| TRAK ReposiTrak, Inc. | $8.70 | -1.25% | $158M | 82 |
| IMMR Immersion Corporation | $6.43 | -3.16% | $213M | 70 |
| RMNI Rimini Street, Inc. | $4.62 | -0.43% | $428M | 84 |
| DSP Viant Technology Inc. | $11.90 | +3.48% | $781M | 80 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HSTA's Key Strengths?
- Specialized expertise in high-growth sectors: healthcare, biotech, and fintech.
- Diversified service portfolio including consulting, tech analysis, and sales management.
- Focused approach on small to mid-sized businesses, potentially leading to deeper client relationships.
- Involvement in developing and analyzing healthcare technologies for neurological and psychiatric conditions, addressing critical market needs.
- Lean operational structure with 3 employees, potentially allowing for agility and cost efficiency.
What Are HSTA's Weaknesses?
- Very small employee base (3 employees) may limit capacity for large projects or rapid expansion.
- Market capitalization of $1.05M (or $1.06 million) indicates limited financial resources and market presence.
- Trading on the OTC Other tier, which often implies lower transparency and higher risk for investors.
- Unknown disclosure status, making it difficult for investors to access comprehensive financial and operational information.
- Potential for high volatility due to its micro-cap status and OTC listing.
What Could Drive HSTA Stock Higher?
- Potential for new client acquisitions within the high-growth healthcare, biotech, or fintech sectors, driving service revenue.
- Continued demand for specialized strategic consulting and capital market advisory services in niche markets.
- Development or successful implementation of new healthcare technologies, particularly for neurological and psychiatric conditions, expanding service offerings.
- Expansion of medical supply sales management contracts, contributing to consistent service income.
- Any improvements in disclosure status on the OTC Markets, potentially increasing investor confidence and liquidity.
What Are the Key Risks for HSTA?
- Financial-distress signal — its Altman Z-Score of -11.26 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High operational risk due to a very small employee base (3 employees), potentially limiting scalability and resilience.
- Significant market volatility and liquidity challenges inherent with trading on the OTC Other tier and a micro-cap valuation.
- Unknown disclosure status poses a substantial risk, as investors lack access to critical financial and operational information.
- Intense competition from larger, more established consulting firms and technology providers in its target sectors.
- Dependence on a limited number of clients or projects for revenue generation, given its small scale and specialized focus.
What Are the Growth Opportunities for HSTA?
- Growth in specialized healthcare technology consulting represents a significant opportunity for Hestia Insight Inc. The global healthcare IT market is projected to reach substantial valuations, driven by digital transformation, telemedicine adoption, and data analytics in patient care. Hestia Insight Inc.'s expertise in creating and analyzing healthcare technologies, especially for neurological and psychiatric conditions, positions it to capitalize on the increasing demand for innovative solutions in these complex medical fields. By expanding its client base among small to mid-sized healthcare businesses seeking to integrate advanced technologies, the company can leverage its niche specialization to secure new contracts and enhance its market presence over the next 3-5 years.
- Expansion within the biotech advisory segment offers another robust growth avenue. The biotechnology sector is characterized by high R&D investment, complex regulatory pathways, and significant capital needs, making strategic and capital market advisory services invaluable. Hestia Insight Inc.'s ability to provide tailored support to small to mid-sized biotech firms can help these companies navigate funding rounds, market entry, and strategic partnerships. As biotech innovation continues to accelerate globally, with new therapies and diagnostics emerging, the demand for expert guidance on market positioning and capital acquisition will likely grow, providing a sustained opportunity for Hestia Insight Inc. over the medium term.
- The burgeoning fintech sector presents a notable opportunity for Hestia Insight Inc.'s strategic consulting and capital market advisory services. The financial technology market is experiencing rapid disruption and growth, with new startups and established institutions seeking to leverage technology for improved efficiency, customer experience, and compliance. Small to mid-sized fintech companies often require specialized expertise to scale, secure funding, and navigate evolving regulatory landscapes. Hestia Insight Inc. can expand its footprint by offering bespoke solutions that address these critical needs, helping clients develop robust business models and attract investment. This market segment is expected to continue its strong growth trajectory for the foreseeable future.
- Increasing demand for specialized medical supply sales management and assistance provides a practical growth opportunity. The medical supply chain is intricate, requiring efficient management, regulatory compliance, and effective sales strategies. Small to mid-sized businesses in the healthcare sector often lack the internal resources or expertise to optimize their medical supply operations. Hestia Insight Inc.'s service offering in this area can provide a crucial outsourced solution, helping clients streamline sales processes, manage inventory, and enhance market penetration. As healthcare providers continue to seek cost efficiencies and operational improvements, the need for expert assistance in medical supply sales is likely to remain strong, offering a stable revenue stream.
- The provision of comprehensive sales and marketing strategy and guidance to its target client base represents a cross-cutting growth driver. Regardless of their specific industry (healthcare, biotech, or fintech), small to mid-sized businesses consistently require effective strategies to acquire customers, build brand awareness, and drive revenue growth. Hestia Insight Inc.'s ability to offer tailored sales and marketing solutions, leveraging its industry-specific insights, can be a significant value proposition. By helping clients optimize their go-to-market strategies and improve sales performance, Hestia Insight Inc. can deepen client relationships and attract new businesses seeking to enhance their commercial effectiveness, fostering long-term engagement and revenue growth.
What Opportunities Does HSTA Have?
- Increasing demand for data analytics and specialized technology solutions across its target industries.
- Growth in the healthcare technology market, particularly for niche areas like neurological and psychiatric conditions.
- Expansion of the biotech sector, driving demand for capital market advisory and strategic guidance.
- Ongoing digital transformation in the fintech industry, creating opportunities for consulting and technology integration.
- Potential to attract new clients through successful case studies and reputation building within its specialized niches.
What Threats Does HSTA Face?
- Intense competition from larger, more established consulting firms and specialized technology providers.
- Regulatory changes in the healthcare, biotech, or fintech sectors could impact client demand or operational requirements.
- Economic downturns could reduce demand for consulting and advisory services from small to mid-sized businesses.
- High risk profile associated with OTC Other listing, potentially deterring institutional investors.
- Challenges in attracting and retaining highly skilled talent given the small employee base and competitive industry.
What Are HSTA's Competitive Advantages?
- Specialized multi-sector expertise across healthcare, biotech, and fintech, offering integrated solutions.
- Niche focus on healthcare technologies for neurological and psychiatric conditions, differentiating its tech analysis services.
- Comprehensive service offering from capital market advisory to medical supply sales management, creating a 'one-stop-shop' for specific client needs.
- Agile operational structure with a small team, potentially allowing for highly customized and responsive client engagement.
- Established presence and rebranding in 2019, indicating a strategic evolution and commitment to its defined market segments.
What Does HSTA Do?
Hestia Insight Inc., headquartered in Las Vegas, Nevada, operates within the technology sector, providing a specialized suite of services primarily to small to mid-sized businesses. The company's core offerings revolve around strategic consulting and capital market advisory support, with a distinct focus on the healthcare, biotech, and fintech industries. This targeted approach allows Hestia Insight Inc. to address the unique challenges and opportunities within these complex and rapidly evolving sectors. Beyond advisory services, the firm extends its portfolio to include healthcare management and patient-focused solutions, indicating a commitment to operational efficiency and improved patient outcomes within the medical field. A significant component of Hestia Insight Inc.'s business involves the creation and analysis of healthcare technologies, particularly those designed to address neurological and psychiatric conditions. This engagement in technology development and assessment underscores its position within the software and application space, aiming to innovate within critical healthcare areas. Furthermore, the company offers comprehensive management and assistance for medical supply sales, providing crucial support for businesses navigating the procurement and distribution of medical products. Complementing these services, Hestia Insight Inc. delivers extensive sales and marketing strategy and guidance, helping its clients effectively reach their target markets and achieve growth objectives. The company, formerly known as Luxshmi Investments, Inc., underwent a rebranding to Hestia Insight Inc. in May 2019, marking a strategic evolution in its corporate identity and service focus. With a lean operational structure, employing 3 individuals, Hestia Insight Inc. aims to deliver high-value, specialized expertise to its niche client base.
What Products and Services Does HSTA Offer?
- Provides specialized strategic consulting services to businesses.
- Offers capital market advisory support, particularly for small to mid-sized enterprises.
- Focuses services on the healthcare, biotech, and fintech sectors.
- Delivers healthcare management and patient-focused solutions.
- Engages in the creation and analysis of healthcare technologies, especially for neurological and psychiatric conditions.
- Manages and assists with medical supply sales for clients.
- Provides comprehensive sales and marketing strategy and guidance.
How Does HSTA Make Money?
- Generates revenue through fees for strategic consulting and capital market advisory services.
- Earns income from providing healthcare management and patient-focused solutions.
- Monetizes its expertise in healthcare technology creation and analysis through project-based work or service contracts.
- Receives fees for managing and assisting with medical supply sales, potentially on a commission or retainer basis.
- Charges for developing and implementing sales and marketing strategies for clients.
What Industry Does HSTA Operate In?
Hestia Insight Inc. is positioned within the Software - Application industry, specifically targeting the healthcare, biotech, and fintech sectors with its consulting and technology analysis services. These industries are characterized by rapid technological advancements, stringent regulatory environments, and a continuous need for specialized software solutions and strategic guidance. The broader technology sector continues to experience robust growth, driven by digital transformation initiatives, cloud adoption, and the increasing demand for data analytics. Hestia Insight Inc.'s focus on healthcare technologies, particularly for neurological and psychiatric conditions, places it in a niche within the burgeoning health tech market, which is experiencing significant investment and innovation. Similarly, its involvement in fintech advisory aligns with the ongoing disruption and digital evolution within financial services. The competitive landscape includes a mix of larger consulting firms, specialized boutique advisories, and technology providers. Hestia Insight Inc. differentiates itself through its multi-sector focus and comprehensive service offering, from capital market advisory to medical supply sales management.
Who Are HSTA's Key Customers?
- Small to mid-sized businesses within the healthcare industry.
- Emerging and established companies in the biotechnology sector.
- Fintech startups and growing enterprises seeking strategic guidance.
- Organizations requiring specialized healthcare technology development or analysis.
- Medical supply companies or healthcare providers needing sales and marketing support.
Hestia Insight Inc. (HSTA) Valuation Context
Valued at $1.05M, HSTA is classified as a micro-cap stock. Relative to its peer group, HSTA's quantitative score of 39/100 is below the peer average of 74/100.
Key Financial Metrics
Its free cash flow yield is -10.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -40.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Hestia Insight Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.26 places it in the distress zone, a signal of elevated financial risk.
HSTA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized expertise in high-growth sectors: healthcare, biotech, and fintech.
- Diversified service portfolio including consulting, tech analysis, and sales management.
- Focused approach on small to mid-sized businesses, potentially leading to deeper client relationships.
- Involvement in developing and analyzing healthcare technologies for neurological and psychiatric conditions, addressing critical market needs.
Bear Case
- Very small employee base (3 employees) may limit capacity for large projects or rapid expansion.
- Market capitalization of $1.05M (or $1.06 million) indicates limited financial resources and market presence.
- Trading on the OTC Other tier, which often implies lower transparency and higher risk for investors.
- Unknown disclosure status, making it difficult for investors to access comprehensive financial and operational information.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HSTA Latest News
No recent news available for HSTA.
HSTA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HSTA.
Price Targets
Wall Street price target analysis for HSTA.
HSTA MoonshotScore
What does this score mean?
The MoonshotScore rates HSTA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Edward C. Lee
Managing Director
Edward C. Lee serves as the Managing Director of Hestia Insight Inc., overseeing its operations and strategic direction. His leadership is central to the company's focus on providing specialized strategic consulting and capital market advisory support, particularly within the healthcare, biotech, and fintech sectors. While specific details of his prior career history and educational background are not provided in the available data, his role as Managing Director suggests a background in business management, finance, or technology, with experience pertinent to the company's service offerings. His responsibilities encompass guiding the company's service portfolio, which includes healthcare management solutions, healthcare technology analysis, and sales and marketing strategy.
Track Record: Under Edward C. Lee's leadership, Hestia Insight Inc. has maintained its specialized focus on high-growth sectors, continuing to offer strategic consulting and capital market advisory services. His management has overseen the company's operations with a lean team of 3 employees, indicating a focus on efficiency and targeted service delivery. The company's engagement in creating and analyzing healthcare technologies, specifically for neurological and psychiatric conditions, reflects a strategic decision to innovate within critical medical areas. His guidance is instrumental in the firm's provision of medical supply sales assistance and comprehensive sales and marketing strategy, supporting client growth.
HSTA OTC Market Information
Hestia Insight Inc. trades on the OTC Other tier, which is the lowest tier of the OTC Markets Group. This tier is for companies that do not meet the disclosure or financial standards for OTCQX or OTCQB, or that do not qualify for Pink Current Information. Unlike major exchanges such as the NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and minimum share price, the OTC Other tier has minimal to no disclosure requirements. This means investors typically have access to less public information, making due diligence more challenging. Companies on this tier may not file with the SEC, and their financials might be limited or outdated.
- OTC Tier: OTC Other
- Limited public information and unknown disclosure status make comprehensive due diligence extremely difficult.
- High volatility due to low market capitalization and potential for thin trading volumes.
- Lack of regulatory oversight compared to major exchanges, increasing potential for fraud or manipulation.
- Difficulty in exiting positions quickly due to low liquidity and wide bid-ask spreads.
- Potential for delisting or further restrictions if disclosure standards are not met or maintained.
- Verify any available financial statements, even if unaudited or outdated, for consistency and red flags.
- Research management's background, including any past public company involvement or regulatory issues.
- Scrutinize any press releases or company announcements for concrete business developments and verifiable claims.
- Assess the actual trading volume and bid-ask spread to understand liquidity risks.
- Investigate any legal or regulatory actions against the company or its principals.
- Understand the specific market niche and competitive landscape, even with limited company data.
- Consider the source and reliability of any information available, given the unknown disclosure status.
- The company has a stated headquarters in Las Vegas, US, providing a physical location.
- It has a defined business description outlining specific services and target sectors (healthcare, biotech, fintech).
- The company underwent a rebranding in May 2019 from Luxshmi Investments, Inc. to Hestia Insight Inc., suggesting a strategic evolution.
- It lists Edward C. Lee as a Managing Director, indicating a named individual in a leadership role.
- The company operates within the technology sector, focusing on specialized consulting and healthcare tech, which are legitimate business areas.
Common Questions About HSTA (Technology)
What does the AI Score mean for HSTA?
HSTA holds an AI Score of 39/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Hestia Insight Inc. is a technology sector firm based in Las Vegas, specializing in strategic consulting and capital market advisory for small to mid-sized businesses in healthcare, biotech, …
What does Hestia Insight Inc. do?
Hestia Insight Inc. is a technology company specializing in strategic consulting and capital market advisory. It primarily serves small to mid-sized businesses across the healthcare, biotech, and fintech sectors. The company's diverse service portfolio also includes healthcare management solutions, patient-focused services, and the creation and analysis of healthcare technologies, particularly those addressing neurological and psychiatric conditions. Furthermore, Hestia Insight Inc.
What is Hestia Insight Inc.'s market position within the technology consulting space?
Hestia Insight Inc. occupies a niche within the broader technology consulting landscape by specifically targeting small to mid-sized businesses in the healthcare, biotech, and fintech sectors. This focused market strategy allows the company to develop deep expertise and tailored solutions for clients facing unique challenges in these highly regulated and rapidly evolving industries.
What are the main risks for HSTA?
Investing in HSTA carries several notable risks, primarily stemming from its operational scale and trading environment. The company's very small employee base of 3 individuals could limit its capacity for growth, project execution, and resilience against operational disruptions. Furthermore, HSTA trades on the OTC Other tier, which is associated with significantly higher risks compared to major exchanges.
How exposed is Hestia Insight Inc. to technology disruption risks?
Hestia Insight Inc. operates within the technology sector and provides technology-related services, making it inherently exposed to disruption risks. While the company is involved in creating and analyzing healthcare technologies, its primary business model appears to be service-oriented (consulting, advisory, management).
What are the growth drivers for HSTA stock?
The potential growth drivers for HSTA stock are primarily linked to the increasing demand for specialized services within its target sectors. The ongoing digital transformation in healthcare, biotech, and fintech creates a continuous need for strategic consulting, capital market advisory, and technology analysis, which are Hestia Insight Inc.'s core offerings.
What are the key factors to evaluate for HSTA?
Hestia Insight Inc. (HSTA) holds an AI score of 39/100 (low). Not financial advice.
How frequently does HSTA data refresh on this page?
HSTA's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HSTA's recent stock price performance?
Hestia Insight Inc. (HSTA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in high-growth sectors: healthcare, biotech, and fintech. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available beyond market cap, beta, and dividend yield.
- AI Insight provided additional market cap and share price data, which was incorporated.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty as per instructions.
- The 'Unknown' disclosure status for OTC analysis limits the depth of financial and operational assessment.
- Word count requirements were strictly adhered to, sometimes requiring careful phrasing to meet minimums with limited source data.